Written by: Jeremiah Moore, PharmD, University of Rochester Medical Center

Download Here

This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed, refractory multiple myeloma (RR-MM), and relapsed, refractory diffuse large b-cell lymphoma (RR-DLBCL) and discuss effective practices to maximize the use of selinexor therapy.

Background:

Selinexor is an oral, selective inhibitor of nuclear export (SINE) that blocks exportin 1 (XPO1).

Selinexor is indicated:

  1. In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
  2. In combination with dexamethasone, for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors (PI), at least 2 immunomodulatory agents (IMiD), and an anti-CD38 monoclonal antibody (mAb)
  3. For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy

 PQI Process:

Upon receiving a new prescription for selinexor

  • Confirm appropriate dosing and schedule based on diagnosis and prescribed regimen (MM, RR-MM or RR-DLBCL)
  • Confirm receipt of dexamethasone (requirement for RR-MM indication only)
  • Confirm prophylactic anti-emetic for moderate to high emetogenicity
  • Advise patients to maintain adequate fluid and caloric intake throughout treatment. Consider intravenous hydration for patients at risk of dehydration
  • Provide prophylactic antiemetics. Administer a 5-HT3 receptor antagonist and other anti-nausea agents (such as NK-1 RA and/or olanzapine) prior to and during treatment with selinexor
  • Ensure appropriate monitoring with a CBC, CMP, and body weight at baseline, then at least weekly for the first 3 months, then at least monthly thereafter. Consider monitoring more frequently during the first three months of treatment
  • Monitor patients closely for side effects including:
    • Cytopenia (thrombocytopenia, anemia, neutropenia)
    • GI intolerance (nausea, vomiting, diarrhea)
    • Fatigue
    • Weight loss
    • Hyponatremia
    • Potential side effects involved with utilizing bortezomib in combination (peripheral neuropathy, blurred vision)
  • Educate patients on side effects and report adverse effects to prescriber

Dosing:

  • RR-MM in combination with dexamethasone Xd: Selinexor 80 mg (4 x 20 mg tablets) by mouth twice weekly on Days 1 and 3 until disease progression or unacceptable toxicity. Dexamethasone 20 mg by mouth twice weekly on Days 1 and 3 until disease progression or unacceptable toxicity
  • MM in combination with bortezomib and dexamethasone XVd: Selinexor is 100 mg (2 x 50mg) by mouth once weekly on day 1 of each week until disease progression or unacceptable toxicity. Bortezomib 1.3 mg/m2 administered subcutaneously once weekly on Day 1 of each week for 4 weeks followed by 1 week off. Dexamethasone 20mg by mouth twice weekly on Days 1 and 2 of each week
  • RR-DLBCL: Selinexor 60 mg (3 x 20 mg tablets) by mouth twice weekly on days 1 and 3 until disease progression or unacceptable toxicity

Supportive Care/Adverse Effect Management

                        Xd Dose Reduction Steps for RR-MM Adverse Reactions

Selinexor starting dose1st Reduction2nd Reduction3rd Reduction 

 

Discontinue

80 mg Days 1 and 3 of each week (160 mg total per week)100 mg ONCE

Weekly

80 mg

ONCE

Weekly

60 mg

ONCE

Weekly

53% of patients had a reduction in dose, and 65% had a dose interrupted3

                                    XVd Dose Reduction Steps for MM Adverse Reactions

Selinexor starting dose 1st

Reduction

2nd Reduction 3rd

Reduction

 

 

Discontinue

100 mg  ONCE Weekly on Day 1 of each week (100 mg total per week) 80 mg

ONCE

Weekly

60 mg 

ONCE

Weekly

40 mg 

ONCE 

Weekly 

64% of patients had a reduction in dose, and 83% had a dose interrupted3

Dose Reduction Steps for RR-DLBCL Adverse Reactions5

Selinexor starting dose 1st Reduction 2nd Reduction 3rd Reduction  

 

Discontinue

60 mg  Days 1 and 3 of each week (120 mg total per week) 40 mg Days 1 and 3 of each week (80 mg total per week) 60 mg  ONCE

Weekly

40 mg ONCE 

Weekly 

                                    49% of patients had a reduction in dose, and 61% had a dose interrupted5

  • Gastrointestinal
    • Dose reduction and/or drug holiday
    • Addition of olanzapine or NK1R antagonist for nausea and vomiting
    • Addition of loperamide for diarrhea
  • Hyponatremia
    • Interrupt when Sodium level ≤ 130 mmol/L
    • Oral and IV fluids and/or salt tablets
  • Weight Loss
    • Interrupt when weight loss between 10% to ≤ 20%
    • Consider Nutritionist consult and supplements such as Boost®, Ensure®
      • Consider addition of low dose olanzapine and/or megesterol acetate

Patient Centered Activities:

  • Provide Oncology Chemotherapy Education (OCE) sheet
  • Consider providing Selinexor (Xpovio®) Treatment Support Kit (TSK)
  • Ensure patient knows dosing schedule including dexamethasone (if applicable) and prophylactic anti-nausea medications
  • Ensure patient knows to swallow the tablet whole with water. The tablet should not be broken, chewed, crushed, or divided
  • Ensure patient knows that blood tests and body weight will be monitored closely
  • Ensure patient knows the importance of maintaining adequate fluid and caloric intake throughout treatment

References:

  1. Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. Journal of Clinical Oncology. 2018; 36: 859-866.
  2. Chen C, Siegel D, Gutierrez M, et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and waldenstrom macroglobulinemia. Blood. 2018; 131(8): 855-963.
  3. Xpovio® (selinexor) [package insert]. Newton, MA: Karyopharm Therapeutics Inc; 2021.
  4. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. New England Journal of Medicine. 2019; 381:727-738.
  5. Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020; 7: e511–22.
Important notice: National Community Oncology Dispensing Association, Inc. (NCODA), has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional.  This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented.  NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.
Victoria

Victoria has blogged 1610 posts

View all PQI